CN119522097A - 5t4抗体-药物缀合物及其用途 - Google Patents

5t4抗体-药物缀合物及其用途 Download PDF

Info

Publication number
CN119522097A
CN119522097A CN202380052757.2A CN202380052757A CN119522097A CN 119522097 A CN119522097 A CN 119522097A CN 202380052757 A CN202380052757 A CN 202380052757A CN 119522097 A CN119522097 A CN 119522097A
Authority
CN
China
Prior art keywords
amino acid
acid sequence
seq
substituted
adc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380052757.2A
Other languages
English (en)
Chinese (zh)
Inventor
西玛·坎塔克
布莱恩·艾伦·孟德尔颂
罗宾·M·巴菲尔德
斯迪潘·丘普拉科夫
佩妮罗普·M·德雷克
亚得林·欧刚科亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Priority to CN202510757191.4A priority Critical patent/CN120571033A/zh
Publication of CN119522097A publication Critical patent/CN119522097A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380052757.2A 2022-05-13 2023-05-10 5t4抗体-药物缀合物及其用途 Pending CN119522097A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510757191.4A CN120571033A (zh) 2022-05-13 2023-05-10 5t4抗体-药物缀合物及其用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263341957P 2022-05-13 2022-05-13
US63/341,957 2022-05-13
PCT/US2023/066811 WO2023220620A2 (en) 2022-05-13 2023-05-10 5t4 antibody-drug conjugates and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510757191.4A Division CN120571033A (zh) 2022-05-13 2023-05-10 5t4抗体-药物缀合物及其用途

Publications (1)

Publication Number Publication Date
CN119522097A true CN119522097A (zh) 2025-02-25

Family

ID=88731090

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202380052757.2A Pending CN119522097A (zh) 2022-05-13 2023-05-10 5t4抗体-药物缀合物及其用途
CN202510757191.4A Pending CN120571033A (zh) 2022-05-13 2023-05-10 5t4抗体-药物缀合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510757191.4A Pending CN120571033A (zh) 2022-05-13 2023-05-10 5t4抗体-药物缀合物及其用途

Country Status (16)

Country Link
US (1) US20250295803A1 (cg-RX-API-DMAC10.html)
EP (1) EP4522157A2 (cg-RX-API-DMAC10.html)
JP (1) JP2025516569A (cg-RX-API-DMAC10.html)
KR (1) KR20250024875A (cg-RX-API-DMAC10.html)
CN (2) CN119522097A (cg-RX-API-DMAC10.html)
AU (1) AU2023268538A1 (cg-RX-API-DMAC10.html)
CA (1) CA3252237A1 (cg-RX-API-DMAC10.html)
CL (1) CL2024003441A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024015381A2 (cg-RX-API-DMAC10.html)
CR (1) CR20240491A (cg-RX-API-DMAC10.html)
DO (1) DOP2024000233A (cg-RX-API-DMAC10.html)
IL (1) IL316790A (cg-RX-API-DMAC10.html)
MX (1) MX2024013869A (cg-RX-API-DMAC10.html)
PE (1) PE20251184A1 (cg-RX-API-DMAC10.html)
TW (1) TW202408585A (cg-RX-API-DMAC10.html)
WO (1) WO2023220620A2 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250060248A (ko) * 2022-09-07 2025-05-07 엑셀리시스, 인코포레이티드 조직 인자 항체-약물 접합체 및 이의 용도
KR20260114567A (ko) * 2023-11-15 2026-07-22 엑셀리시스, 인코포레이티드 5t4 항체 약물 접합체 및 이의 사용 방법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020006010A (es) * 2017-12-11 2020-10-16 Triphase Res And Development Iii Corp Conjugados de anticuerpo anti-cd22-maitansina, combinaciones y metodos de uso de los mismos.

Also Published As

Publication number Publication date
TW202408585A (zh) 2024-03-01
PE20251184A1 (es) 2025-04-23
US20250295803A1 (en) 2025-09-25
WO2023220620A3 (en) 2023-12-14
CA3252237A1 (en) 2023-11-16
CR20240491A (es) 2025-01-07
KR20250024875A (ko) 2025-02-19
CO2024015381A2 (es) 2025-02-24
CN120571033A (zh) 2025-09-02
WO2023220620A2 (en) 2023-11-16
CL2024003441A1 (es) 2025-02-28
DOP2024000233A (es) 2025-02-28
MX2024013869A (es) 2024-12-06
IL316790A (en) 2025-01-01
JP2025516569A (ja) 2025-05-30
EP4522157A2 (en) 2025-03-19
AU2023268538A1 (en) 2024-11-21

Similar Documents

Publication Publication Date Title
TW202241521A (zh) 生物活性物偶聯物及其製備方法和用途
CN114269389B (zh) 靶向紧密连接蛋白18.2的抗体药物偶联物
WO2019170131A1 (zh) 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途
CN104936621A (zh) 抗IL-13受体α2抗体和抗体-药物缀合物
EP4603109A1 (en) Antibody-drug conjugate, preparation method therefor, and use thereof
KR20160113623A (ko) 항체-약물 접합체 및 면역독소
CN114127117B (zh) 用于偶联的多肽复合物及其应用
WO2024109944A1 (zh) 抗liv-1抗体、其药物偶联物及其医药用途
CN115368461A (zh) 抗trop-2抗体、其抗体-药物偶联物及其医药用途
CN120571033A (zh) 5t4抗体-药物缀合物及其用途
TW202545993A (zh) 抗dll3抗體、核酸分子、載體、細胞、藥物綴合物或融合蛋白及其用途
KR20240040098A (ko) 넥틴-4에 특이적인 항체 및 항체 접합체 및 이의 사용방법
CN116568707A (zh) 一种抗体药物偶联物及其医药用途
CN114652853A (zh) 抗il-4r抗体-药物偶联物及医药用途
CN120129535A (zh) 组织因子抗体-药物缀合物及其用途
WO2023046003A1 (zh) 抗体药物偶联物及其制备方法和医药用途
WO2026021443A1 (en) Antibody-drug conjugates targeting cdh3 and preparation methods and uses thereof
CN121752598A (zh) 酪氨酸蛋白激酶膜受体1 (ror1)抗体-药物缀合物和其用途
HK40129540A (en) Cdh17-targeting antibody and adc and use thereof
WO2025261511A1 (zh) 靶向cdh17的抗体和adc及其应用
HK40079580B (en) Bioactive substance conjugate, preparation method therefor and use thereof
HK40121296A (en) Bioactive conjugate, and preparation method therefor and use thereof
CN118119644A (zh) 具有人源化框架区的抗体
CN118043328A (zh) 对nectin-4特异性的抗体和抗体缀合物及其使用方法
CN120282965A (zh) 黏蛋白-1特异性抗体缀合物及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination